Here are five important observations:
1. Spinal Modulation is the developer of the Axium Neurostimulator System, which can be used in the stimulation of the dorsal root ganglion to provide pain relief.
2. Following the completion of the acquisition, St. Jude Medical will become the only medical device manufacturer to offer radiofrequency ablation, spinal cord stimulation and dorsal root ganglion stimulation therapy solutions for chronic pain.
3. Upon closing the deal, St. Jude Medical will make a payment of approximately $175 million for the company.
4. The Axium system received CE Mark approval in November 2011, and in December 2014, Spinal Modulation announced that enrollment in its ACCURATE U.S. IDE trial had been completed. The company has now submitted its pre-market approval application to the FDA.
5. St. Jude Medical is a global medical device manufacturer focusing on developing technologies in four major clinical areas — cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation.
More articles on devices:
Multi-purpose, flexible coils enhance image quality of existing MRI machines
DePuy Synthes, Stryker, Zimmer, Medtronic lead global orthopedics now — 8 key notes on where they’re headed
Foreign currency exchange rocks Exactech: Net income down 2% — 10 key notes
